TNFRSF9 and head and neck squamous cell carcinoma: To understand the role of circulating CD137+ T cells in (R/M) HNSCC patients undergoing pembrolizumab treatment, we evaluated the levels of CD137+ T cells derived from the peripheral blood of the 40 cancer patients before beginning immunotherapy.